Patent Licensing: Terms, Royalties & Exclusivity

Once a patent issues — or even while an application is still pending — the work of a university technology transfer office (TTO) shifts from protecting an invention to moving it into use. That shift happens through a license: a contract granting a company (or, in some cases, a newly formed spinout) the right to make, use, or sell the patented technology, in exchange for payment and a set of obligations. This guide covers that post-issuance stage — how a license is structured, how it’s priced, and how the negotiation differs depending on who’s on the other side of the table. For how a patent gets to this point in the first place, see CASRAI’s guides on provisional patent applications, patent term, the cost of filing a patent, and the dictionary entry on patent prosecution.

What a Patent License Actually Grants

A patent license does not transfer ownership of the patent. The university (or, for federally funded inventions elected under the Bayh-Dole Act, 35 U.S.C. §§ 200-212) keeps title. What the licensee receives is permission not to be sued for practicing rights the patent owner otherwise controls exclusively: making, using, selling, offering to sell, or importing the claimed invention. That distinction matters for how the rest of the agreement is built — everything downstream (exclusivity, field-of-use, royalties, diligence obligations) is really a set of conditions attached to that permission, not terms of a sale.

The Association of University Technology Managers (AUTM) is the professional body whose Licensing Activity Survey and practice materials define much of the shared vocabulary US and Canadian TTOs use for this stage — exclusive vs. non-exclusive counts, running-royalty-bearing licenses, and startup/small-company license categories all trace back to how AUTM’s survey defines these terms for annual reporting. The Licensing Executives Society’s Certified Licensing Professional (CLP) credential organizes the same subject matter into a recognized competency sequence — opportunity assessment and valuation, agreement drafting, negotiation, and agreement management — that roughly matches the order this guide follows below.

Exclusive, Non-Exclusive, and Sole Licenses

Three license types cover most university patent deals:

Exclusive license — only one licensee may practice the patent (within whatever field-of-use and territory the license defines); the university grants no other license covering the same rights, and — depending on the agreement’s drafting — may also give up its own right to practice the invention itself.
Non-exclusive license — the university can license the same patent, in the same field, to any number of other companies. The licensee gets freedom to operate, not market exclusivity.
Sole license — a middle case: the university commits not to license any other third party, but retains its own right to practice the invention (e.g., to keep licensing know-how updates, or to continue related research).

The choice tracks the size of investment the licensee has to make to bring the technology to market. A peer-reviewed overview of university technology commercialization published in JACC: Basic to Translational Science frames the logic directly: exclusive licenses are generally warranted “when the licensee is making a high-risk investment,” while non-exclusive licenses fit better when “the invention is a broadly useful process that may appeal to multiple licensees” — a platform method or research tool, for example, rather than a single drug candidate that needs years of clinical development before it generates any revenue (Van Norman & Eisenkot, “Technology Transfer: From the Research Bench to Commercialization, Part 2,” 2017). A company asked to spend tens of millions of dollars on regulatory trials for a single compound has little incentive to do so if a competitor can license the same patent and free-ride on that investment — exclusivity is what makes the economics work. A broadly applicable research tool, by contrast, generates more total value non-exclusively licensed to many users than it would locked up with one.

Field-of-Use and Territory Restrictions

Exclusivity rarely means “exclusive for every possible application, everywhere, forever.” Most university licenses narrow exclusivity along one or both of two axes:

Field-of-use — the license is exclusive only within a defined application area. A single invention can be licensed exclusively to one company for one therapeutic use and, separately, to a different company for an unrelated diagnostic or industrial use, because the two fields don’t compete with each other. This lets a university capture value from a broadly useful invention without giving one licensee blanket control over every downstream market.
Territory — exclusivity is limited to a geographic market (e.g., North America), leaving the university free to license the same field-of-use elsewhere.

Both restrictions are drafted narrowly and specifically on purpose: an ambiguous field-of-use definition is one of the more common sources of later licensing disputes, because “does this new product fall inside or outside the licensed field” is exactly the kind of question that becomes commercially contentious once a licensee starts generating real revenue.

How University Patent Licenses Are Priced

Consideration in a patent license is rarely a single number — it’s typically a combination of several payment types, each doing a different job.

Upfront fees

A one-time payment due at signing, meant to reimburse the university’s patenting costs to date and signal the licensee’s commitment. Upfront fees on early-stage academic technology are commonly modest — often well under six figures — because the technology is unproven and the licensee is still taking on most of the development risk. Universities frequently reduce or waive the upfront fee entirely for a startup licensee with no operating revenue, and take equity or a deferred payment structure instead (see below).

Running royalties

An ongoing payment, almost always calculated as a percentage of the licensee’s net sales of products covered by the licensed patent, paid for as long as the license and the underlying patent rights remain in force. Reported royalty rates for university-originated patents vary widely by field and stage of development — industry and TTO sources commonly describe a broad range of roughly 1% to 10% of net sales, with rates in the low-to-mid single digits (commonly cited as clustering around 2%-6%) more typical than either extreme for a life-sciences or engineering invention licensed at an early stage. Treat any specific percentage as a starting point for negotiation, not a fixed benchmark — the actual rate in a given deal reflects the technology’s stage of development, the size of the addressable market, how much additional investment the licensee still has to make, and how strong the patent claims are, not a standard published rate.

Milestone payments

Fixed payments triggered by the licensee hitting a defined development or regulatory checkpoint — a first prototype, an IND filing, entry into a clinical trial phase, or a regulatory approval, for example. Milestones let the university share in a technology’s value as it de-risks over time without having to price all of that uncertainty into the upfront fee, and they double as diligence checkpoints: a licensee that never hits its first milestone is a licensee that may not be developing the technology at all (see diligence obligations, below).

Equity

For a startup licensee with no product revenue to base a royalty on, many universities take an equity stake in the company — in place of, or in addition to, a reduced upfront fee — as part of the license consideration. Equity aligns the university’s return with the startup’s eventual success (or acquisition/IPO) rather than with near-term royalty income that a pre-revenue company can’t yet pay.

Sublicensing Rights

Whether — and on what terms — a licensee may sublicense the patent to a third party is a separately negotiated term, not something that follows automatically from exclusivity. Universities commonly grant sublicensing rights to an exclusive licensee (particularly a startup that may need to sublicense to a larger commercialization partner, a distributor, or a manufacturing partner as it scales), but attach conditions: the university’s prior written consent, a share of any sublicense-related income (upfront fees and royalties the licensee collects from its own sublicensees), and a requirement that sublicenses carry forward the same diligence, reporting, and compliance obligations the primary license imposes. Non-exclusive licenses typically carry no sublicensing right at all — there’s usually no reason for the university to let a non-exclusive licensee extend rights to still more parties it hasn’t itself vetted.

Diligence Obligations and Managing the License After Signature

Signing a license is the start of the university’s oversight role, not the end of it. Because exclusive rights effectively take a technology off the market for anyone else, TTOs build in diligence obligations to guard against a licensee sitting on a patent without developing it — commonly a development plan with named milestones and dates, minimum annual royalty payments regardless of actual sales (so an exclusive licensee can’t simply stop selling and keep the rights dormant), periodic progress and sales reporting, and a termination right if the licensee materially fails to perform. Ongoing license management — tracking reporting deadlines, auditing royalty reports against actual sales where the agreement allows it, and enforcing diligence milestones — is a distinct, continuing function separate from the negotiation that produced the agreement, and is one of the four core competency areas the CLP credential (cited above) organizes licensing practice around.

Negotiating With a Startup or Spinout vs. an Established Licensee

The commercial substance of a license — what rights are granted, on what terms — doesn’t change based on who the licensee is, but the negotiation dynamics and the specific terms that get used to solve for risk do differ in fairly predictable ways.

Startup or spinout licensee

Little or no ability to pay a substantial upfront fee, so cash consideration is typically reduced or deferred, and equity is a common substitute or supplement.
A faculty-inventor founder creates a conflict-of-interest that the institution has to review and manage separately from the licensing negotiation itself — the same person is often on both sides of the deal in substance, even though the license is formally between the institution and the company.
Diligence milestones tend to be structured around fundable checkpoints (seed funding closed, prototype built, first regulatory filing) rather than sales-based thresholds, since a pre-revenue company has no sales to measure against yet.
Because the company doesn’t exist as an operating entity until the license (or an option to license) is in place, the license itself is frequently a condition the startup’s investors require to close a funding round — timing the license to the company’s fundraising calendar is a real, recurring negotiation constraint.

Established company licensee

Typically able to pay a meaningful upfront fee and has existing sales, manufacturing, and regulatory infrastructure that can shorten the path to market — which is itself a negotiating point in the university’s favor on royalty rate and milestone value.
Due diligence runs in the other direction too: an established licensee’s legal and technical teams scrutinize the patent’s claims, freedom-to-operate, and prosecution history far more rigorously before signing than an early-stage startup typically has the resources to.
Negotiations more often center on scope (field-of-use carve-outs so the license doesn’t block the university’s ability to license adjacent applications elsewhere) and on representations/warranties around inventorship, ownership, and third-party rights, since an established company has more to lose from a later validity or ownership challenge.

Between those two poles sits the option agreement — a short-term, lower-cost right to evaluate a technology and negotiate a license later, on terms to be worked out (or pre-agreed) once the option is exercised. Startups and early-stage companies commonly take an option first, particularly while raising the capital needed to support a full license.

The Extra Layer for Federally Funded Inventions

When the underlying patent covers a “subject invention” under Bayh-Dole — one conceived or first reduced to practice with federal funding — licensing carries obligations beyond what a purely privately funded patent does. Two are worth knowing specifically because they only apply here:

The federal government retains a nonexclusive, paid-up, irrevocable license to practice the invention itself, regardless of who the university licenses it to (37 CFR 401.14(b)) — this survives any subsequent license the university grants.
An exclusive license to use or sell the invention in the United States generally requires the licensee to agree that products embodying the invention will be manufactured substantially in the United States, under 35 U.S.C. § 204’s domestic manufacturing preference — a real, statutory constraint on exclusive licensing terms that doesn’t apply to non-federally-funded patents. The funding agency can waive this requirement if the patent holder shows reasonable efforts to find a licensee willing to manufacture domestically were unsuccessful, or that domestic manufacture isn’t commercially feasible.

Utilization and royalty reporting for these inventions generally flows through iEdison, the interagency system federal agencies use to track federally funded invention disclosures and commercialization status — see CASRAI’s guide to iEdison invention reporting for the disclosure and reporting deadlines that precede this licensing stage. Industry-sponsored inventions made without federal funding sit outside Bayh-Dole entirely, governed instead by whatever the underlying sponsored research agreement negotiated — see CASRAI’s guide on industry-university research partnerships for how those IP terms get set.

Frequently Asked Questions

What is the difference between an exclusive and a non-exclusive patent license?

An exclusive license grants rights to only one licensee within the defined field and territory; the university cannot license the same rights to anyone else. A non-exclusive license lets the university license the same patent to multiple companies at once. Exclusivity is generally used when a licensee needs to make a large, high-risk investment to commercialize the technology; non-exclusive licensing fits broadly useful inventions with multiple potential users.

How are patent royalty rates determined?

There is no fixed or published standard rate — royalty rates are negotiated per deal based on the technology’s stage of development, market size, remaining development cost and risk, and the strength of the patent claims. Reported ranges across university licensing commonly span roughly 1% to 10% of net sales, with low-to-mid single digits more typical for early-stage academic technology than either end of that range.

What is a field-of-use restriction?

A field-of-use restriction limits an exclusive license to a defined application area (e.g., a specific therapeutic use, or a specific industrial process), allowing the university to license the same underlying patent exclusively to a different company for a different, non-competing application.

Can a patent licensee sublicense to a third party?

Only if the license agreement grants that right, which is a separately negotiated term rather than something implied by exclusivity. When granted, sublicensing rights are typically conditioned on the university’s consent, a share of sublicense income, and a requirement that the sublicense carry forward the primary license’s diligence and compliance obligations.

How does licensing to a university spinout differ from licensing to an established company?

A spinout typically can’t pay a large upfront fee and often exchanges equity for reduced cash consideration; the university also has to manage a faculty-founder conflict of interest that doesn’t arise with an arm’s-length established licensee. An established company typically pays more upfront and brings existing infrastructure that can accelerate commercialization, but scrutinizes the patent’s validity and freedom-to-operate more heavily before signing.

What happens if a licensee doesn’t meet its diligence milestones?

Most university licenses give the university the right to terminate (or convert an exclusive license to non-exclusive) if the licensee materially fails to meet development milestones, fails to pay minimum annual royalties, or otherwise fails to diligently commercialize the technology — the specific remedy depends on how the agreement’s diligence and termination clauses are drafted.

Patent Licensing: Exclusive Terms, Royalties, and Startup vs. Established Deals